New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 30, 2014
13:15 EDTEXASExact Sciences could rise 50%, Barron's says
Exact Sciences shares could rise 50% fit the company's colon cancer test ramps up quickly, Barron's contends in a feature article. Short sellers are betting heavily against the company, the paper adds. Reference Link
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
14:39 EDTEXASExact Sciences Cologuard to be approved in August or September, says Mizuho
Subscribe for More Information
07:37 EDTEXASExact Sciences reports Q2 EPS (24c), consensus (25c)
Exact reported total revenues of $0.0 million for the second quarter of 2014, compared to $1.0 million for the second quarter of 2013.
07:08 EDTEXASLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use